Dec. 20th, 2024 - Irvine, California --(AINewsworthy)-- Leonhardt Ventures LLC is pleased to announce the issuance of U.S. Leonhardt et. al. Patent 12,109,410 with 15 claims entitled “Bioelectric Stimulator”, a significant advancement in the field of regenerative medicine. This patent, granted on October 8th, 2024, provides Lionheart Health, Inc., BioLeonhardt LTP, Valvublator, Inc., EyeCell, EarCell, KidneyCell, BladderCell, CerebraCell, CancerCell and other Leonhardt Ventures LLC spin out startups with exclusive rights to this pioneering patent for bioelectric stem cell homing, proliferation and differentiation control for regenerating tissues and organs and extending healthspan longevity.

Claims include a method of using a bioelectric stimulator to stimulate target tissue of a subject to control stem cell homing, proliferation, or differentiation and/or upregulate expression of at least one protein by the target tissue, wherein the protein is selected from the group consisting of activin, epidermal growth factor (EGF), follistatin, hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), platelet-derived growth factor (PDGF), receptor activator of nuclear factor kappa-B ligand (RANKL), stromal cell-derived factor 1 (SDF1), tropoelastin, vascular endothelial growth factor (VEGF) and any combination thereof.

This core platform technology is being applied to over 38 applications of use https://leonhardtventures.com/development-pipeline/ including (1) Heart & Cardiovascular, (2) Brain Health, (3) Major Organ Regeneration, (4) Medical Aesthetics and (5) Cancer.

Lionheart Health, Inc. http://www.lionhearthealthstim.com is applying this technology into its products and study protocols for skin and hair regeneration, body toning, sexual health, joint health and healthspan longevity.

BioLeonhardt http://www.bioleonhardt.com, Valvublator, Inc. and AortaCell to heart, heart valve and aorta regeneration.

CerebraCell http://www.cerebracell.com is applying it to applications for stroke and TBI recovery. MemoryStim http://www.memory-stim.com for applications in treating dementia and Alzheimer's in combination with klotho therapy.

PancreaCell, KidneyCell, RegenaLung and LiverCell are applying it to major organ regeneration https://leonhardtventures.com/major-organ-regeneration/. In the case of PancreaCell also as a treatment for diabetes. BladderCell to bladder health.

CancerCell http://www.cancercellinc.com is applying is cancer treatment.

"Being able to recruit stem cells where you want to when you want to in the body and then multiple them and control their differentiation is a major breakthrough in organ regeneration research" stated Dr. Jorge Genovese VP of Bioelectric Research.

About Leonhardt Ventures LLC:

Founded in 1982 Leonhardt Ventures LLC (HJ Leonhardt & Co.) is a long standing leader in the development of medical innovations. Over 600,000 patients have been treated with Leonhardt inventions to date http://www.leonhardtventures.com

Contacts:

Howard J. Leonhardt
Leonhardt Ventures LLC

Lionheart Health, Inc.
1 Kent Court
Mission Viejo, CA 92694
http://www.leonhardtventures.com

http://www.lionhearthealthstim.com

http://www.lionheartongevity.com

This press release is distributed by Newsworthy.ai. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Leonhardt Ventures LLC and Licensee Lionheart Health, Inc. Granted U.S. Patent for Bioelectric Stem Cell Homing, Proliferation & Differentiation.